RNS Number : 6042R
Kromek Group PLC
07 July 2022

7 July 2022

Kromek Group plc
("Kromek" or the "Group")

Kromek enters agreement with Smiths Detection Inc.

Agreement to deliver radiation detection equipment to North & South America

Kromek Group plc, a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, announces that it has entered into a distribution agreement with Smiths Detection Inc. ("Smiths"), a global leader in threat detection and security screening technologies.

Under the terms of the agreement, Smiths will distribute the Group's wearable radiation detection and identification solutions to North and South American markets. Smiths will be focused on marketing and distributing Kromek's D3 and D5 series of wearable radiation detectors, which are designed to enable first responders, armed forces, border security and other CBRN experts to detect radiological threats such as dirty bombs, radioactive contamination and smuggling of radioactive substances.

Smiths Detection, part of Smiths Group, is a global leader in threat detection and screening technologies for aviation, ports and borders, defence and urban security markets. Its experience and history across more than 40 years at the frontline, enables Smiths Detection to deliver the solutions needed to protect society from the threat and illegal passage of explosives, prohibited weapons, contraband, toxic chemicals and narcotics.

Dr Arnab Basu, Chief Executive Officer of Kromek, said:

"*We are delighted to partner with Smiths Detection, which has been at the forefront of providing solutions needed to protect society for over four decades. Our wearable D3 and D5 family of products are closely aligned to the needs of Smiths Detection's customer base and complement their existing product offering. We look forward to working with Smiths Detection to deliver our solutions to customers across North and South America.*"

For further information, please contact:

Kromek Group plc
Arnab Basu, CEO — +44 (0)1740 626 060
Paul Farquhar, CFO

finnCap Ltd (Nominated Adviser and Broker)
Geoff Nash/Kate Bannatyne/George Dollemore - Corporate Finance — +44 (0)20 7220 0500
Tim Redfern/Charlotte Sutcliffe - ECM

Luther Pendragon (Financial PR)
Harry Chathli/Claire Norbury — +44 (0)20 7618 9100

About Kromek Group plc

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has

manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation technology, are primarily used to protect critical infrastructure and urban environments from the threat of 'dirty bombs'.

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.

Further information is available at www.kromek.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

AGRDBGDRRBGDGDL